文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重症脓毒症患者持续与间断输注β-内酰胺类抗生素:BLING III随机临床试验

Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论在重症脓毒症患者中,持续输注β-内酰胺类抗生素较间断输注未显著降低90天全因死亡率(24.9% vs 26.8%,P=0.08),但临床治愈率更高(55.7% vs 50.0%)。

BLING III是一项在澳大利亚、比利时、法国、马来西亚、新西兰、瑞典和英国104个ICU开展的国际、开放标签、随机临床试验,纳入≥18岁因脓毒症接受哌拉西林-他唑巴坦或美罗培南治疗的危重症成人,随机接受等效24小时剂量的持续输注(n=3498)或间断输注(n=3533)。主要终点90天全因死亡率在持续输注组为24.9%(864/3474),间断输注组为26.8%(939/3507),绝对差异-1.9%(95%CI -4.9%至1.1%),OR 0.91(95%CI 0.81至1.01),P=0.08,未达统计学显著。临床治愈率持续输注组55.7%(1930/3467)高于间断输注组50.0%(1744/3491),绝对差异5.7%(95%CI 2.4%至9.1%)。其他次要终点无统计学差异。

要点

  • 在104个ICU的7202例随机脓毒症患者中,持续输注β-内酰胺类抗生素90天死亡24.9%(864/3474),间断输注26.8%(939/3507),绝对差异-1.9%(95%CI -4.9%至1.1%),OR 0.91(95%CI 0.81至1.01),P=0.08,未达统计学显著。
  • 持续输注组临床治愈率55.7%(1930/3467),间断输注组50.0%(1744/3491),绝对差异5.7%(95%CI 2.4%至9.1%)。
  • 持续输注与间断输注在耐多药微生物或艰难梭菌感染的新发获得、定植或感染、ICU死亡率及住院死亡率等其他次要终点上无统计学差异。
  • 作者指出,90天死亡率效应估计的置信区间既包括无重要效应,也包括持续输注可能带来临床重要获益。

适用人群与场景

  • ≥18岁危重症成人,因脓毒症接受哌拉西林-他唑巴坦或美罗培南治疗,来自澳大利亚、比利时、法国、马来西亚、新西兰、瑞典和英国的104个ICU。

处置流程与药物剂量

  • 符合条件的患者随机接受等效24小时剂量的β-内酰胺类抗生素(哌拉西林-他唑巴坦或美罗培南),通过持续输注(n=3498)或间断输注(n=3533)给药,疗程由临床医生决定或直至ICU出院,以先发生者为准。

研究设计与关键结果

  • 研究类型:国际、开放标签、随机临床试验;104个ICU;招募时间2018年3月26日至2023年1月11日,随访于2023年4月12日完成。
  • 共7202例随机,7031例(97.6%)符合知情同意要求纳入主要分析;平均(SD)年龄59(16)岁,女性2423例(35%)。
  • 主要终点90天全因死亡率:持续输注组24.9%(864/3474)vs 间断输注组26.8%(939/3507),绝对差异-1.9%(95%CI -4.9%至1.1%),OR 0.91(95%CI 0.81至1.01),P=0.08。
  • 临床治愈(随机后14天内):持续输注组55.7%(1930/3467)vs 间断输注组50.0%(1744/3491),绝对差异5.7%(95%CI 2.4%至9.1%)。
  • 其他次要终点(随机后14天内耐多药微生物或艰难梭菌感染的新发获得、定植或感染;ICU死亡率;住院死亡率)无统计学差异。

证据类型、等级与局限

  • 证据类型:国际、开放标签、随机临床试验(BLING III),ClinicalTrials.gov注册号NCT03213990。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,持续输注与间断输注β-内酰胺类抗生素在90天死亡率上的观察差异未达统计学显著,但效应估计的置信区间既包括无重要效应,也包括持续输注可能带来临床重要获益。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Whether β-lactam antibiotics administered by continuous compared with intermittent infusion reduces the risk of death in patients with sepsis is uncertain.

OBJECTIVE: To evaluate whether continuous vs intermittent infusion of a β-lactam antibiotic (piperacillin-tazobactam or meropenem) results in decreased all-cause mortality at 90 days in critically ill patients with sepsis.

DESIGN, SETTING, AND PARTICIPANTS: An international, open-label, randomized clinical trial conducted in 104 intensive care units (ICUs) in Australia, Belgium, France, Malaysia, New Zealand, Sweden, and the United Kingdom. Recruitment occurred from March 26, 2018, to January 11, 2023, with follow-up completed on April 12, 2023. Participants were critically ill adults (≥18 years) treated with piperacillin-tazobactam or meropenem for sepsis.

INTERVENTION: Eligible patients were randomized to receive an equivalent 24-hour dose of a β-lactam antibiotic by either continuous (n = 3498) or intermittent (n = 3533) infusion for a clinician-determined duration of treatment or until ICU discharge, whichever occurred first.

MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality within 90 days after randomization. Secondary outcomes were clinical cure up to 14 days after randomization; new acquisition, colonization, or infection with a multiresistant organism or Clostridioides difficile infection up to 14 days after randomization; ICU mortality; and in-hospital mortality.

RESULTS: Among 7202 randomized participants, 7031 (mean [SD] age, 59 [16] years; 2423 women [35%]) met consent requirements for inclusion in the primary analysis (97.6%). Within 90 days, 864 of 3474 patients (24.9%) assigned to receive continuous infusion had died compared with 939 of 3507 (26.8%) assigned intermittent infusion (absolute difference, -1.9% [95% CI, -4.9% to 1.1%]; odds ratio, 0.91 [95% CI, 0.81 to 1.01]; P = .08). Clinical cure was higher in the continuous vs intermittent infusion group (1930/3467 [55.7%] and 1744/3491 [50.0%], respectively; absolute difference, 5.7% [95% CI, 2.4% to 9.1%]). Other secondary outcomes were not statistically different.

CONCLUSIONS AND RELEVANCE: The observed difference in 90-day mortality between continuous vs intermittent infusions of β-lactam antibiotics did not meet statistical significance in the primary analysis. However, the confidence interval around the effect estimate includes the possibility of both no important effect and a clinically important benefit in the use of continuous infusions in this group of patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03213990.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024. PMID: 38864155. doi:10.1001/jama.2024.9779

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。